Dossier assessment
Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with severe thrombocytopenia and chronic liver disease who are scheduled to undergo an invasive procedure
- Moderate or high bleeding risk of the invasive procedure: proof of considerable added benefit.
- Low bleeding risk of the invasive procedure: added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021-09-16 A G-BA decision was published.
Project details
- Project no.
- A21-31
- Commission
- Commission awarded on 22.03.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Avatrombopag (primary chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31
Status: Commission completed